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StabilityHuman glucose 6-phosphate dehydrogenase (G6PD) has both the “catalytic” NADP+ site and a “structural”
NADP+ site where a number of severe G6PD deﬁciency mutations are located. Two pairs of G6PD clinical
mutants, G6PDWisconsin (R393G) and G6PDNashville (R393H), and G6PDFukaya (G488S) and G6PDCampinas (G488V),
in which the mutations are in the vicinity of the “structural” NADP+ site, showed elevated Kd values of the
“structural” NADP+, ranging from 53 nM to 500 nM compared with 37 nM for the wild-type enzyme. These
recombinant enzymes were denatured by Gdn-HCl and refolded by rapid dilution in the presence of L-Arg,
NADP+ and DTT at 25 °C. The refolding yields of the mutants exhibited strong NADP+-dependence and ranged
from 1.5% to 59.4% with 1000 μM NADP+, in all cases lower than the ﬁgure of 72% for the wild-type enzyme.
These mutant enzymes also displayed decreased thermostability and high susceptibility to chymotrypsin
digestion, in good agreement with their corresponding melting temperatures in CD experiments. Taken
together, the results support the view that impaired binding of “structural” NADP+ can hinder folding as well as
cause instability of these clinical mutant enzymes in the fully folded state.© 2009 Elsevier B.V. All rights reserved.1. IntroductionThe pentose phosphate pathway (PPP) enzyme glucose 6-
phosphate dehydrogenase (G6PD, EC 1.1.1.49; MIM# 305900) pro-
vides NADPH, vital, amongst other roles, in protecting cells against
oxidative stress. The deﬁciency of G6PD in human red blood cells
affects more than 400 million people and can cause severe disease
phenotypes, mainly neonatal jaundice and haemolytic anemia [1–3].
In the light of the resolved 3-D structure of human G6PD [4–6],
extensive studies have been carried out to elucidate the molecular
mechanisms underlying G6PD deﬁciency, which potentially include
protein instability, decreased catalytic efﬁciency, and altered dimer-
ization [7–9]. Among these molecular defects, the low levels of G6PD
activity in red blood cells have been mainly attributed to the
instability of the protein, since, over 3–4 months in circulation, the
non-nucleate mature erythrocytes cannot synthesize new enzymes to
replenish lost activity. However, instability alone cannot account
convincingly for low levels of G6PD activity that are also sometimes
found in cases with reticulocytosis, where, by deﬁnition, the enzyme
will have been recently synthesized.
Recently, several papers have also reported that G6PDmutations in
different locations could affect the refolding ability in vitro, correlatingenase; CD, circular dichroism;
e monohydrochloride; DTT,
: +00353 1 283 7211.
ll rights reserved.with decreased stability of the enzymes but almost unaltered kinetic
properties [10–12]. If these results also correlate with the ability of the
enzyme to fold in vivo, it would suggest that, with some clinical
mutations, even young erythrocytes would have depleted G6PD levels.
If variants cannot fold with efﬁciency comparable to that of the WT
enzyme, this also leaves them both prone to aggregation and
susceptible to protease degradation in vivo.
Human G6PD has two NADP+ binding sites per subunit. One is the
“catalytic” site, and the other is the “structural” site. Although the tightly
bound NADP+ at this latter site is not directly involved in the enzyme-
catalysed reaction, previous studies have shown that many severe Class
I G6PD deﬁciencymutations are located in the dimer interface and close
to the “structural” NADP+ site [5]. The auxiliary cofactor molecule is
thought to be crucial for the stability and integrity of active enzyme [13].
Furthermore, it has also been reported that NADP+ is required for
monomer hybridization and refolding [10,11,14–16].
Several clinical mutations close to the “structural” NADP+ binding
site, e.g. G6PDWisconsin (nt1177 C→G, R393G), G6PDNashville (nt1178
G→A, R393H), G6PDFukaya (nt1462 G→A, G488S) and G6PDCampinas
(nt1463 G→T, G488V), have been found to affect the binding capacity
for the additional NADP+ molecule [9,13], although R393 mutations
are located in the dimer interface and also affect the dimerization
process. Whether impaired binding of “structural” NADP+ might also
damage the folding of the mutant enzymes is still uncertain. Recently,
we have developed a reproducible, high-yield refolding protocol, and
it is clear that the presence of the coenzyme is critical in recovering
the majority of the G6PD in its correctly folded, active form [14]. This
protocol is, therefore, applied here to test these four clinical mutants
Fig. 1. Thermostability of G6PD WT and mutant enzymes. G6PD wild-type and mutant
enzymes were incubated for 20 min at different temperatures together with various
concentrations of added NADP+, and residual activities were measured. The transition
temperature, T1/2, at which 50% of original activity is retained under each set of
experimental conditions was recorded.
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addition, tests of stability and susceptibility to protease digestion and
CD experiments were carried out to further elucidate the importance
of the “structural” NADP+.
2. Materials and methods
2.1. Materials
Restriction enzymes, calf intestinal alkaline phosphatase, DNA
modifying enzymes, and DNA markers were purchased from NEBio-
labs (USA). Agarosewas fromGIBCO BRL Life Technologies (USA). DNA
Miniprep kit and Gel extraction kit were from QIAGEN (USA). All the
oligonucleotide primers for both mutagenesis and DNA sequencing
were purchased from GIBCO BRL.
NADP+ and NADPH were obtained from Apollo Scientiﬁc Ltd (UK),
and 2′5′ADP-Sepharose 4Bwas fromGEHealthcare. EDTA-free protease
inhibitor cocktail was from Roche. Glucose 6-phosphate, guanidinium
hydrochloride (Gdn-HCl), L-arginine monohydrochloride, dithiothreitol
(DTT), polyethylene glycol (PEG, MW 3350), Trizma base, and TLCK-
treated chymotrypsin, all of reagent grade or better, were from Sigma.
Spectrophotometric and ﬂuorimetric measurements were made
throughout with a Cary Bio50 spectrophotometer and a Hitachi F-4500
ﬂuorimeter. Protein secondary structure was examined with a J810
spectropolarimeter from JASCO (UK).
2.2. Construction, expression and puriﬁcation of recombinant proteins
The recombinant proteins, G6PD R393G, R393H, G488V and
G488S, corresponding to the clinical mutants G6PD Wisconsin,
Nashville, Campinas and Fukaya were expressed in E. coli and puriﬁed
to homogeneity as previously reported [9,13].
2.3. Kinetic characterization of G6PD wild-type and mutant enzymes
Steady-state kinetic studies and the thermostability tests on the
recombinant enzymes were carried out as previously reported
[8,9,13,17]. In brief, reaction mixtures contained 0.01 M MgCl2 in
0.1 M Tris–HCl buffer, pH 8.0 with varying amounts of sugar phosphate
and coenzyme in a total volume of 1 ml. NADP+ concentrations ranged
from 1 to 75 μM and G6P concentrations from 10 to 1000 μM. Reaction
was initiated by adding enzymes, typically in 10 μl, to give a linear
ﬂuorescence increase for at least the ﬁrst 2 min.
2.4. Thermostability tests
Puriﬁed wild-type and mutant enzymes, freed from loosely bound
NADP+ by serial dilution using Centricon YM-50, were adjusted to
0.01 mg/ml protein concentration. NADP+ was added back to give
concentrations of 1 μM, 10 μM, 100 μM and 1 mM. All samples were
incubated at various temperatures (25 °C–65 °C at 5 °C intervals) for
20 min and subsequently cooled to 4 °C. Residual activity was
expressed as a percentage of the activity for the same sample
measured at 25 °C before incubation.Table 1
Steady-state kinetic parameters of G6PD wild type, R393G, R393H, G488V and G488S.
Enzyme Speciﬁc activity (IU/mg) ϕo (s) ϕNADP+ (μMs) ϕG
WTa 180±10 0.00366±0.00023 0.0259±0.0041 0.1
R393Ga 178±8 0.0043±0.00032 0.0402±0.0092 0.2
R393Ha 130±9 0.0052±0.0005 0.0853±0.0067 0.9
G488V 160±8 0.00472±0.0002 0.0502±0.0018 0.2
G488S 175±9 0.00397±0.0002 0.0471±0.0013 0.1
The table shows the speciﬁc activities of G6PD wild-type and mutant enzymes, and their Dalz
and the true Km values for both substrates are also listed. The parameters in each case were
a The data for G6PD WT, R393G and R393H were from Wang et al. [9].2.5. Protease digestion of G6PD wild-type and mutant enzymes
Chymotrypsin was used to probe the proteolytic sensitivity of
G6PD WT and mutants. G6PD samples were diluted to a ﬁnal protein
concentration of 0.01 mg/ml. Chymotrypsin (0.05 mg/ml) and
different amounts of NADP+ from 1 μM to 1000 μM were added to
individual samples. The mixtures were kept at room temperature and
the residual G6PD activity was measured at intervals. Control samples
without protease kept over 90% of their activity throughout the
incubation.
2.6. Determination of dissociation constant of “structural” NADP+
To determine the dissociation constant of “structural” NADP+, as
described elsewhere [9,13], in brief, the puriﬁed enzyme, from which
any loosely bound NADP+ had previously been removed by serial
dilution, was incubated at room temperature with 1 mM glucose 6-
phosphate for 30 min before removing NADPH by passing down a
Sephadex G-75 column pre-equilibrated and eluted with the usual
0.1 M Tris–HCl buffer at pH 7.6. The “stripped” G6PD (5 nM subunits)
was titrated with a concentrated solution of NADP+ added with a
Hamilton syringe. Protein ﬂuorescence at 345 nm was monitored after
exciting at 290 nm. The power settingwas 950Wand the slit 10/10 nm.
The resulting data were ﬁtted to the equation for a single binding
constant with the help of the GOSA software package (Global
Optimisation by Simulated Annealing) from Bio-Log (Toulouse, France).
2.7. Protein unfolding and refolding
Puriﬁed recombinant G6PD wild-type and mutant enzymes (2–
4 mg/ml) were reduced and denatured by 20 mM DTT and 4 M Gdn-
HCl in 50 mM Tris–HCl, pH 7.6 at 30 °C for 2 h. The unfolded proteins
were diluted rapidly into the optimised refolding buffer [14] contain-
ing 500 mM L-Arg, 50 mM NaCl, 10 mM DTT, 40 mM PEG 3350 and
varying concentrations of NADP+ in 50 mM Tris, pH 8.0. The refolding6P (μMs) ϕNADP+G6P (μM2 s) kcat (s−1) KmNADP+ (μM) KmG6P (μM)
91±0.021 1.61±0.22 275±18 7.07±1.13 52±4
88±0.018 3.47±0.59 232±16 9.31±2.4 67.1±13
92±0.11 12.1±0.57 192±18 16.5±2.7 190±27
53±0.011 2.77±0.102 212±8.7 10.7±0.06 53.8±3.44
94±0.006 3.44±0.067 254±5.5 11.8±0.4 49.1±3.2
iel parameters of the reciprocal initial-rate equation [30]. The corresponding kcat values
obtained from three independent experiments.
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followed.
2.8. Circular dichroism analysis
Far-UV CD spectra (200–260 nm) of G6PD wild type and mutants
(0.15 mg/ml) were recorded at 25 °C on a JASCO J-810 CD spectro-
polarimeter with a thermal Peltier temperature controller using a 2mm
path length cuvette. All reported spectra are averages of multiple scans
with appropriate baseline subtraction. The thermostability of G6PDWTFig. 2. Susceptibility of G6PDWTandmutants to chymotrypsin in the presence of different co
room temperature with chymotrypsin (0.05 mg/ml) in the presence of different concentr
activities were followed.and mutant enzymes was also studied by following the change in CD at
222 nm as temperature was increased at 2 °C/min.
3. Results
3.1. Kinetic properties of human G6PD wild type and mutants
Table 1 shows the kinetic properties of human G6PDwild-type and
mutant enzymes. The detailed kinetic properties of G6PD clinical
mutants G488S and G488V have not been reported previously. Here,ncentrations of NADP+. G6PDWTandmutant enzymes (0.01 mg/ml) were incubated at
ations of NADP+ ranging from 1 μM to 1000 μM and corresponding residual enzyme
Fig. 3. Refolding yields of G6PD WT and mutant enzymes in the presence of different
concentrations of NADP+. G6PDWT and mutant enzymes were denatured in 4 M Gdn-
HCl and refolded in 50 mM Tris, pH 8.0 containing 500 mM L-Arg, 50 mM NaCl, 10 mM
DTT, 40 mM PEG 3350 and varying concentrations of NADP+ at 25 °C. The regained
enzyme activity was followed and the recovery yield was calculated based on the ratio
of refolded enzyme activity to the activity before denaturation.
Fig. 4. Far-UV CD spectra of G6PD WT and mutant enzymes. Protein concentration was
0.15 mg/ml and the light path was 2 mm.
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in order to compare with published data for WT G6PD and R393
mutants [9]. The puriﬁed recombinant mutant enzymes, G488V and
G488S, have speciﬁc activities at 160 IU/mg and 175 IU/mg
respectively, quite similar to 180 IU/mg for WT enzyme, but a little
higher than the R393H (130 IU/mg) mutant. The kcat values (1/ϕo) of
G6PD G488S and G488Vwere 254 s−1 and 212 s−1, only slightly lower
than that of the WT (275 s−1), but comparable to R393G (232 s−1)
and R393H (192 s−1), indicating that the maximal catalytic efﬁciency
was only moderately affected by the mutations. In addition, the Km
values of G6PD G488V and G488S for NADP+ (ϕNADP+/ϕo) were
10.7 μM and 11.8 μM respectively, about 1.5-fold higher than the value
for the WT enzyme, implying that the mutations had some slight
negative effects on coenzyme binding at the catalytic site. By contrast,
the Km values for the substrate G6P for these mutants were unaltered
within statistical error (approx. 50 μM). In comparison, the Km for G6P
increased almost four-fold (190 μM) in R393H and to a much smaller
extent (67 μM) in R393G.
3.2. Thermostability of G6PD WT and mutant enzymes
The stability of G6PDWTandmutant enzymes was examined with
increasing temperatures in the presence of different concentrations of
NADP+. R393G was as stable as the WT, whereas the other mutants
R393H, G488V and G488S were all quite unstable (Fig. 1). The
transition temperature, T1/2, is deﬁned for each enzyme as the
temperature at which 50% of its original activity is retained under
current experimental conditions. At the physiological concentration of
NADP+ (around 10 μM), T1/2 for bothWT and R393G was above 50 °C,
about 10 °C higher than the values for R393H (42 °C), G488V (37 °C)
and G488S (41 °C). However, all the enzymes became more stable
when the added concentrations of NADP+ increased, and this NADP+-
dependent stabilisation is more obvious for the R393H, G488V and
G488S mutants.
3.3. Susceptibility to chymotrypsin digestion
The susceptibility of G6PD wild-type and the mutant enzymes to
chymotrypsin was examined in the presence of different concentra-
tions of NADP+. Fig. 2 shows that the mutant enzymes G488S and
especially G488V were very unstable in the presence of 0.05 mg/ml
chymotrypsin at room temperature. At 10 μM NADP+, T50, the time atwhich 50% of the original activity is retained after incubating with
chymotrypsin, was only 8 min and 5 min respectively for G488S and
G488V, a much shorter time than 50 min for the WT enzyme. When
the concentration of NADP+ increased, the mutant enzymes became
more resistant to chymotrypsin; T50 increased to 32 min for G488S
and 8 min for G488V in the presence of 1000 μMNADP+, but was still
much shorter than 80 min for theWT enzyme under these conditions.
However, the mutant enzymes showed more marked protection by
NADP+ against chymotrypsin compared with the WT enzyme. As to
the other mutant enzymes, R393G, like the WT enzyme, was quite
stable compared with the other mutants whereas R393H was very
vulnerable to chymotrypsin, showing a similar pattern to G488S.
3.4. Dissociation constant of “structural” NADP+
A ﬂuorescence titration approach [9,13] was applied to determine
the dissociation constants of the WT and mutant enzymes for
“structural” NADP+. The ﬁgures for the WT, R393G, R393H, G488V
and G488S were 37 nM, 53 nM, 500 nM, 480 nM, and 273 nM,
respectively, as previously reported [9,13].
3.5. Refolding of G6PD WT and mutants
Although the mutations in these clinical variants affect the binding
capacity for “structural” NADP+, which has been reported to be
important for the stability and integrity of folded, active enzyme, it
has not been clear until now whether these mutants are also impaired
in their folding properties. Investigation of this aspect of the defective
proteins depends on a reliable procedure for obtaining reproducible
levels of folding for human G6PD in vitro. Unfolding and refolding
experiments on the mutant enzymes were therefore carried out
according to the method recently established for the WT enzyme [14].
As with WT G6PD, refolding of the mutant enzymes was slow, taking
about 7 days to reach the maximum yield (data not shown). Without
added NADP+, the refolding yields were low, with only around 10% for
the WT and R393G, and undetectable activity for R393H, G488S and
G488V (Fig. 3). In the presence of 200 μM NADP+, the ﬁnal recovery
yield of R393G was 56.2%, a little lower than 69% for the WT. As for
G488S, the yield increased signiﬁcantly to about 16.4%. However, even
with this level of NADP+, the mutants R393H and G488V still regained
hardly any activity. The recovery yields increased further when higher
concentrations of NADP+ were used, and this NADP+-dependent
pattern was predictably more prominent for the mutants G488S,
G488V and R393H. With 1000 μM NADP+ the recovery yields only
increased marginally for theWT enzyme (from 69% to 72%) and R393G
(from 56.2% to 59.4%). In contrast, the refolding yields increased about
Fig. 5. Changes in the CD signal at 222 nm with increase of temperature for G6PD WT
and four clinical mutants.
Fig. 6. 3-D structure of dimer interface in human G6PD and the locations of “structural”
NADP+, Arg393, Arg487 and Gly488.
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G488S (from 16.4% to 29.8%). However, even in this case, the recovery
yields of R393H and G488V were still very low (Fig. 3).
3.6. Secondary structure of G6PD WT and mutant enzymes
Since the mutant enzymes have low binding capacity for
“structural” NADP+ and impaired refolding ability, it was necessary
to check whether this reﬂected a wider structural disruption rather
than a local defect. The secondary structures of the clinical mutants
were examined by measuring the CD spectra in the far UV region
(200–260 nm). The CD spectra of the mutant enzymes were
comparable in pattern and intensity to the native enzyme (Fig. 4),
indicating that the mutations did not signiﬁcantly alter the secondary
structures of the proteins once folded.
Although the secondary structures of the WT and the mutant
enzymes are similar, the stability of these structures showed
signiﬁcant differences at elevated temperatures. The melting tem-
peratures (midpoint of the transition), the temperatures at which half
of the secondary structure is disrupted, were around 55.5 °C for WT
and R393G, higher than 50 °C for R393H. As to the G488 mutants,
G488V was very unstable, losing half of the secondary structure at
45.5 °C, even lower than G488S at 48.5 °C (Fig. 5).
4. Discussion
It has long been proposed that human G6PD has a second
“structural” NADP+ binding site in addition to the “catalytic” site
[18–22]. Conﬁrmation from the 3-D crystal structure of human
G6PDCanton [5], reveals that the “structural” NADP+ is tightly bound
between the β sheets in the dimer interface and the C-terminus, well
separated from the catalytic coenzyme binding site. Remarkably, more
than 40 severe G6PD Class I deﬁciencymutations, e.g. R393, G488, and
P489 mutations [23–28], are located in a distinct regionwhich is close
to the “structural” NADP+ and interface dimerization sites, attracting
inescapable attention to the roles of the auxiliary NADP+ and the
dimer interface. Previous study showed that mutation of Asp421 in
the dimer interface to neutral (A or N) and positively charged (K or R)
residues could increase the thermostability and reduce the NADP+-
dependent stabilising effect by ﬁxing the enzyme conformationwith a
strong electrostatic attraction, indicating that the compactness and
integrity of the dimer interface is crucial for the NADP+-independent
stability of the enzyme [29].
Recent studies, in which it has become possible to measure the
dissociation constant for the tightly bound “structural” NADP+ [9,13],have shown that some naturally-occurring mutations in the cluster
mentioned above cause dramatically decreased afﬁnity for the
auxiliary coenzyme molecule. From the 3-D structure, Gly 488 is
located in the βO–αo turn of the C-terminus, important in positioning
Arg 487 to interact with the adenine and the 2′-phosphate of
“structural” NADP+ directly (3.01 Å) (Fig. 6). If Gly 488 was mutated
to Val or Ser, the larger side chains of these two amino acid residues
might impede the binding of “structural” NADP+, leading the clinical
mutants G6PDCampinas (G488V) [23] and G6PDFukaya (G488S) [24] to
show severe deﬁciency. The determined Kd values for G488S and
G488V were in fact 273 nM and 480 nM, respectively, about 7 and 13-
fold higher respectively than the ﬁgure for wild-type enzyme (37 nM)
[13]. As for Arg 393, it is at the end of the sheet βL in the dimer
interface and the atoms Nη1 and Nη2 of this residue interact with
the nicotinamide amide oxygen of the “structural” NADP+ (2.99 Å)
(Fig. 6). The decreased binding capacity for “structural” NADP+ in
the mutant enzymes G6PDWisconsin (R393G) [25] (Kd∼53 nM) and
G6PDNashville (R393H) [26] (Kd∼500 nM), could also account for the
disease phenotypes [9].
In view of the fact that mature red blood cells lack a nucleus and
cannot synthesize proteins, structural instability of the mutant
enzyme is a likely cause of haemolytic anemia associated with G6PD
deﬁciency. Such instability, however, may affect not only the half-life
of active enzyme once formed but also the proportion of newly-
synthesized enzyme molecules that are able to achieve the correctly
folded state. The results reported here clearly show that the four
mutations mentioned, which would appear in the ﬁrst instance to
exercise their deleterious effect at the molecular level by interfering
with binding of the “structural” NADP+, also impair the refolding
process in vitro and thus, in all probability, the formation of active
enzyme in vivo. Importantly, the decreased refolding yields of the
mutant enzymes (Fig. 3) correlate well with the corresponding lower
binding capacity for “structural”NADP+, strongly suggesting that such
NADP+ is actively involved in the refolding process under current
experimental conditions.
By contrast, the steady-state kinetic studies showed that the
mutant enzymes had quite similar catalytic efﬁciency, kcat, to WT
G6PD and nearly unaltered Km values for the substrates (Table 1).
Likewise, the secondary structure of the enzymes examined by the CD
spectra in the far UV region showed that there is no signiﬁcant
difference in the secondary structure between theWTand the mutant
enzymes (Fig. 4).
The mutant enzymes with low afﬁnity for “structural” NADP+, e.g.
R393H, G488S and G488V, were more susceptible to chymotrypsin
digestion compared with WT or mutant enzymes with relatively high
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counteract the vulnerability of all enzymes to proteolytic digestion
in a concentration-dependent manner, which is more prominent for
the mutant enzymes. In keeping with these results, mutants with low
afﬁnity for “structural”NADP+ also showed decreased thermostability
(Fig. 1). The transition temperature, T1/2, of the WT enzyme is about
10 °C, or even more, higher than the mutants R393H, G488V and
G488S in the presence of different concentrations of NADP+. Once
again, the low stability of G6PD mutants could be compensated to a
certain extent by adding high concentrations of NADP+, and this
NADP+-dependent effect was more signiﬁcant for the mutant
enzymes. The difference in the thermostability between the WT and
mutant enzymes was further conﬁrmed by the secondary structure
change at elevated temperatures (Fig. 5). Secondary structures of
WT and R393G began to disrupt at about 52 °C, whereas R393H,
G488S and G488V began to lose their secondary structures at 47 °C,
45 °C, and 42 °C, respectively, indicating that although the native
secondary structures of the mutant enzymes are very similar to the
WT, the mutant enzymes with low binding afﬁnity for “structural”
NADP+ are less stable, tending to lose the compact structures at
relatively low temperatures.
All of the four G6PD deﬁciency mutants discussed above
reportedly belong to Class I, with less than 5% G6PD activity in the
red blood cells, accompanying the disease phenotype of chronic non-
spherocytic haemolytic anemia. However, so far no clinical data for
G488S and only limited amounts of information about the other three
mutants are available. As to G6PD Wisconsin (R393G), although it is
classiﬁed as Class I, the biochemical properties studied here did not
show a signiﬁcant difference from the wild-type enzyme, raising a
question as towhether the observed Class I phenotypewas dependent
on environmental challenge or on the individual genetic background.
In contrast, the other three mutants, i.e. R393H, G488V and G488S, all
exhibited dramatically decreased stability and impaired refolding
capacity, and needed high concentrations of NADP+ to compensate
these defects, correlating well with their corresponding disease
phenotypes. Among these mutants, G488V seems most severe.
Considering the difﬁculty of obtaining adequate G6PD deﬁcient
human blood samples, the recombinant proteins are still quite useful
for evaluating the relative severity of the mutations based on
measurements of stability, folding capacity, catalytic efﬁciency, afﬁnity
for substrates, etc.
In summary, it seems likely that “structural” NADP+ in human
G6PD plays important roles in both attaining and maintaining the
native state. Folding defects and instability, caused by mutations
located around the “structural” NADP+ site, are thus responsible for
the disease phenotypes of the mutant enzymes. However, it must be
borne in mind that in vitro refolding studies cannot fully reﬂect the
situation in vivo. Also, the possible role of the catalytic NADP+ in the
folding of G6PD still needs to be investigated.
Finally, in view of the key role of a lowmolecular weight additive in
controlling both folding and subsequent stability of G6PDmolecules, it
may be asked whether this offers any prospect of clinical remediation.
NADP+ itself is an unlikely candidate, since it is difﬁcult to envisage
efﬁcient therapeutic delivery to the required site of action. Current
information also indicates a high degree of speciﬁcity in binding at the
structural NADP+ site. However, the possibility cannot be ruled out
that a synthetic compound may be found with both a high afﬁnity for
this site and an ability to cross membranes. Its possible utility as a
drug would then depend on not interfering with other NADP+ roles
in the body.Acknowledgements
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